Can Checkpoint Inhibitors Jump-Start Glioblastoma Drug Development?

The recent failure of Celldex’s vaccine Rintega was disappointing, but that has not dampened researchers’ enthusiasm for immunotherapy in the high-risk, high-reward glioblastoma field.